More articles from GU

You have access
Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
Jingjing Zhang, Christiane Schuchardt, Harshad Kulkarni, Xiaoyuan Chen and Richard P. Baum

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2547;
You have access
Diagnostic accuracy of 99mTc-Sestamibi SPECT/CT with visual and quantitative interpretation for the characterization of solid renal lesions
Ashwin Singh Parihar, Joyce Mhlanga, Carrie Ronstrom, Lisa Schmidt, Robert Figenshau, Farrokh Dehdashti and Richard Wahl

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2617;
You have access
Comparison of [68Ga]Ga-PSMA-617 PET/CT and [68Ga]Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study
Romain Schollhammer, Grégoire Robert, Julien Asselineau, Mokrane Yacoub, Delphine Vimont, Nicolas Balamoutoff, Franck Bladou, Antoine Benard, Hindié Elif, Henri de Clermont Gallerande and Clement Morgat

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2619;
You have access
Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd Krause, Michael Lassmann, Walter Jentzen, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-Rene Basque and Jens Kurth

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2626;
You have access
The impact of concomitant use of androgen deprivation therapies (ADT) on the efficacy of piflufolastat F 18-PET/CT in patients with prostate cancer: a sub-group analysis of OSPREY Cohort B
Lawrence Saperstein, Steven Rowe, Kenneth Pienta, Ajjai Alva, Mark Preston, Frédéric Pouliot, Peter Carroll, Akash Patnaik, Stephan Probst, Bela Denes, Nancy Stambler, Barry Siegel and Michael Morris

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2625;
You have access
Predictive variables of clinical outcomes of indeterminate bone lesions at [18F]-DCFPyL PET/CT imaging
Tim Phelps, Stephanie Harmon, Esther Mena, Liza Lindenberg, Deborah Citrin, Peter Pinto, Bradford Wood, William Dahut, James Gulley, Ravi Madan, Peter Choyke and Baris Turkbey

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2624;
You have access
Radiology-Pathology correlation of 18F-DCFPyL PSMA PET and multi-parametric prostate MRI in men with prostate cancer
Changhee Lee, Shane Wells, Wei Huang, David Jarrard and Steve Cho

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2545;
You have access
Optimal 68Ga-PSMA PET/CT imaging in assessment of prostate cancer: feasibility of only delayed acquisition using a total-body PET/CT scanner?
Xiaofeng Yu, Lian Xu, Jiajin Li, Ying Wang, Jianjun Liu and Yumei Chen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2544;
You have access
Percutaneous transgluteal Ga-68 PSMA PET/CT guided prostate biopsy: Is it the future?
Rajender Kumar, Bhagwant Mittal, Shrawan Kumar Singh, Harmandeep Singh and Anish Bhattacharya

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2542;
You have access
Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy
Sara Harsini, Don Wilson, Heather Saprunoff, Hayley Allan, Martin Gleave, Larry Goldenberg, Kim Chi, Charmaine Kim-Sing, Scott Tyldesley and Francois Benard

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2543;

Main menu

User menu

Search

More articles from GU

Pages